Compugen Ltd. (CGEN)
Discovers and develops cancer-fighting antibody drugs that boost the immune system's ability to attack tumors.
$2.26-0.05%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+52.7%
The outlook
CGEN trades at $2.26, sitting roughly midway in its 52-week range with mixed momentum against moving averages. All five analysts covering the stock rate it a Strong Buy, with an average price target implying about 104% upside from current levels. The low trailing P/E of 5.9 and concentrated analyst bullishness contrast with near-term technical softness.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 5 analysts
Price trendMixed vs its moving averages
52-week range49% of the way from its 52-week low to high
Price targetAvg target +104% vs current price
Analyst price target
~12-month · 5 analysts$4.60average target+103.5% vs now
Now $2.26
Low $4.00High $6.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$213.8M
52-wk high
$3.24
52-wk low
$1.30
50-day avg
$2.33
200-day avg
$2.07
Trailing P/E
5.9